Shannon McWeeney, Ph.D., works at the intersection of computer science, biostatistics, genetics and medicine, finding ways to speed cancer research past the bottlenecks stalling progress. She’s...
Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...
Cancer clinical trials that use less-reliable shortcut endpoints save relatively little time, according to an analysis of 107 cancer drugs approved for 188 indications from 2006 to 2017. Image:...
The Beat AML clinical trial has matched 250 study participants to targeted treatments for acute myeloid leukemia – with promising early results. Regulators were wary of the complicated study...
The VA Portland Health Care System is one of 12 centers across the U.S. selected for a national initiative to give military veterans more opportunities to participate in cancer clinical trials. The...
Osteosarcoma is a bone cancer that disproportionately affects teenagers, and outcomes for patients have changed little in decades. Now researchers, including two OHSU Knight Cancer Institute...
Q&A: Prostate cancer expert Julie Graff, M.D., explains how a new treatment option fills a void for men with resurgent tumors. When prostate cancer isn't cured by surgery or radiation, the...
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
Five oncologists at Oregon Health & Science University in Portland will receive a $25,000 salary supplement for one year, allowing them to reserve time to pursue promising research...
A precision oncology clinical trial in the works at the OHSU Knight Cancer Institute gained a $25,000 pledge from Intel Corp. The company said it will contribute the money by means of a fund...
At the recent European Society for Medical Oncology meeting, OHSU oncologist Julie Graff, M.D., presented the first evidence of meaningful clinical activity for PD-1 blockade in men with...